Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

mifepristone

mifepristone

9 results

Filter Results By

Filter Applied. Clear All

Latest Posts

May 13, 2024 New Study Reveals FDA Relied on Cherrypicked Data to Approve Dangerous Mail-Order Abortion Drugs New Study Reveals FDA Relied on Cherrypicked Data to Approve Dangerous Mail-Order Abortion Drugs May 9, 2024 Abortion Reporting: Oklahoma (2023) Abortion Reporting: Oklahoma (2023) April 30, 2024 Gestational Limits on Abortion in the United States Compared to International Norms (April 2024) Gestational Limits on Abortion in the United States Compared to International Norms (April 2024)
Reset All Filters
9 results
mifepristone

Induced Abortion with Misoprostol Alone

As abortion limits have been implemented in many states in the wake of the Supreme Court’s Dobbs decision, some perplexing recommendations have been advanced by abortion advocates and their media allies.

Ingrid Skop, M.D., FACOG
May 18, 2023
ClosePlease login
mifepristone

Lozier Institute Statement on Abortion Pill Lawsuit Filed by Alliance Defending Freedom

Charlotte Lozier Institute, which in 2021 revealed a dramatic surge in abortion pill-related emergency room visits, today applauded Alliance Defending Freedom for challenging the U.S. Food and Drug Administration’s (FDA) erroneous and highly-politicized approval of the abortion drug regimen.

mifepristone

Dangerous Deception: Not Telling Your Doctor About Abortion Pill Use Increases Health Risks

A new analysis of 423,000 confirmed abortions debunks the common abortion industry narrative that “there’s no medical reason to tell a doctor about an abortion.”

mifepristone

Overlooked Dangers of Mifepristone, the FDA’s Reduced REMS, and Self-Managed Abortion Policies: Unwanted Abortions, Unnecessary Abortions, Unsafe Abortions

The failure of abortion providers to support and undertake prospective longitudinal studies of a nationally representative sample of women contributes to our belief that the ideological biases of abortion providers have led to a combination of disinterest, willful ignorance, or even a conspiracy to hide the widespread dangers of unwanted and contraindicated abortions.

mifepristone

Public Health Threat: Connecticut DPH Data Shows More Women Using Risky Abortion Method

Half of all Connecticut abortions are performed with potentially dangerous drugs which multiple peer-reviewed studies have linked to higher rates of complications.

mifepristone

Public Health Threat: Chemical Abortion Leads to Significantly Higher Rate of ER Visits

As the Food and Drug Administration (FDA) works toward a December 16 decision on chemical abortion safeguards, a groundbreaking new study from Charlotte Lozier Institute (CLI) shows that increased access to abortion pills creates a significant public health risk.

featured-image
mifepristone

FDA’s Race to Defend Women From Dangerous Drugs

Abortion advocates—seeking to exploit the COVID-19 crisis to advance unfettered access to abortion-inducing drugs—found a friend in federal court.  In mid-July, Judge Theodore D. Chuang issued a preliminary injunction prohibiting the Food and Drug Administration (FDA) from enforcing certain health and safety practices that abortion providers are required to follow when prescribing the only FDA-approved abortion drug regimen.

featured-image
mifepristone

Issues in Law and Medicine Spring 2017 Summaries

Issues in Law and Medicine is a peer-reviewed professional journal that has been published twice a year since 1985. It is currently cosponsored by the Watson Bowes Research Institute and the National Legal Center for the Medically Dependent & Disabled, Inc.  The new issue (spring 2017) includes a fine article by CLI associate scholar Nora Sullivan, M.P.A., cowritten with Dr. Eoghan de Faoite., an Irish physician committed to the sanctity of human life.

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image